Dear Editor,

We read with interest the Editorial by Kondili et al. about the potential pitfalls found in studies in which SARS-CoV-2 testing is combined with point-of-care-testing (POCT) HCV screening. We do agree that the representativeness of the target population could be a problem in such pilot studies. In addition, it could be speculated that socioeconomically deprived people could face barriers to being engaged in HCV and SARS-CoV-2 combined screening programs.

The SARS-CoV-2 pandemic caused a significant challenge for the WHO roadmap—which aimed to achieve HCV elimination by 2030—with detrimental effects in terms of excess mortality, especially in the lower middle-income groups. Italy is considered to be the country with the highest HCV seroprevalence in Western Europe, with up to 280,000 people estimated to be unaware of their HCV status and thus unlinked to care. Currently, in Italy, an active free of charge HCV screening is offered to all subjects belonging to the 1969–1989 birth cohort, to intravenous drug users and convicts. Our group has previously shown the feasibility of a combined SARS-CoV-2 and HCV Ab POCT screening in three small towns in Lombardy, finding 72 HCV Ab positive subjects out of 2505 screened. Nevertheless, we were unable to assess the proportion of HCV RNA-positive subjects, the linkage-to-care acceptance rate, and antiviral treatment eventually received for HCV. In addition, it is still unknown whether a similar screening program would be feasible and effective in a major city neighbourhood characterized by low socio-economic status context. Consequently, in our study, we aimed to assess the HCV Ab status using POCT in subjects undergoing COVID-19 screening in the San Siro social-housing neighbourhood of Milan, with a multi-ethnic population and low socio-economic status, and the subsequent acceptance of linkage-to-care.

Study procedures have been described elsewhere. In brief, we conducted a cross-sectional prevalence study for the detection of HCV Ab IgG performed on capillary peripheral blood via a rapid immunochromatographic test (RICT) (OraQuick HCV Test OraSure Technologies Inc.) contextually with the detection of anti-SARS-CoV-2 IgG (rapid test SARS-CoV-2 IgM-IgG gold; Technogenetics) performed on capillary peripheral blood and a rapid nasopharyngeal swab for SARS-CoV-2 (Rapid Test COVID-19 Ag; Technogenetics) between 23 December 2020 and 19 February 2021.

We set our study in the San Siro neighbourhood in north-western Milan.

The primary aim of the study was to estimate the prevalence of HCV Ab positivity through POCT. The secondary aim was to assess the proportion of linkage-to-care acceptance.

People currently living in the neighbourhood and aged >39 years at the time of the HCV Ab screening were eligible to participate in the study. A questionnaire was administered to obtain epidemiological information and clinical history. Skilled healthcare workers performed and read RICTs and a physician was always present to confirm the results and address patients’ questions.

During the first 14 days of the SARS-CoV-2 screening, HCV-Ab RICTs were always readily available, whilst they were not always present during the following screening period due to supply problems.

Every subject who tested positive for HCV-Ab RICT and were unaware of their serostatus, and/or who declared to be aware of an untreated HCV infection were contacted by telephone and HCV-Ab serology and HCV-RNA quantitative PCR on peripheral blood were arranged at Luigi Sacco Hospital (Milan). Treatment and follow-up were then offered when an active HCV infection was confirmed.

Subjects who did not answer the phone call on two different occasions were considered lost to follow-up.

Out of 2394 subjects who participated in the screening for SARS-CoV-2, 1637 subjects were over 39 years of age, of whom 691 (42.2%) were screened for HCV Ab by RICTs (Table 1). During the first 14 days of the screening, when the HCV Ab RICTs were readily available, 310 out of 322 eligible subjects (96%) accepted to be screened for HCV. The median age was 64 years (inter quartile range [IQR] 54–74) and 435 subjects (62.9%) were female. Five hundred-fifty-three subjects (80%) had at least one Italian parent and 138 (20%) had no Italian parents.

Seventeen subjects (2.5%) tested positive for HCV-Ab RICTs. They were predominantly females (64.7%) with a median age of 70 years (IQR 60–80); two subjects belonged to the 1969–1989 birth-cohort and 15 to the <1969 birth-cohort. Fourteen subjects (82.4%) were born in Italy, one (5.9%) was from Egypt, one from Argentina and one from Colombia. Most subjects (82.4%) reported no risk factors for HCV infection. Two subjects (11.8%) reported a history of intravenous drug use. Five subjects (29.4%) were unaware of their serological status. Out of the 12 subjects aware of their
serological status, eight (66.7%) reported to have been successfully treated for HCV.

A graphical representation of subjects reporting a previous HCV infection in the questionnaire according to the results of HCV Ab RICTs is depicted in Figure 1. Nineteen subjects who tested negative reported a previous HCV infection in the questionnaire of whom 10 reported HCV treatment, and 9 (90%) stated that they were treated more than 5 years ago.

We contacted the five subjects who tested positive and declared themselves unaware of their serological status. During the phone call, three patients declared they were already followed/treated at other hospitals. One patient born in Egypt was

---

TABLE 1 Characteristics of the study population according to being tested positive or not for HCV with RICTs

|                          | Overall, n = 691 (100%) | Positive, n = 17 (2.5%) | Negative, n = 674 (97.5%) |
|--------------------------|-------------------------|-------------------------|---------------------------|
| Age, median (IQR)        | 64.0 (54.0–74.0)        | 70.0 (60.0–80.0)        | 63.5 (54.0–74.0)          |
| Sex, n (%)               |                         |                         |                           |
| Female                   | 435 (63.0)              | 11 (64.7)               | 424 (62.0)                |
| Male                     | 256 (37.0)              | 6 (35.3)                | 250 (37.0)                |
| WHO regions, n (%)       |                         |                         |                           |
| Europe and Central Asia  | 564 (81.6)              | 14 (82.4)               | 550 (81.6)                |
| America                  | 33 (4.8)                | 2 (11.8)                | 31 (4.6)                  |
| East Asia and Pacific    | 10 (1.4)                | 0 (0.0)                 | 10 (1.5)                  |
| Middle East and North Africa | 39 (5.6)          | 1 (5.9)                 | 38 (5.6)                  |
| South Asia               | 8 (1.2)                 | 0 (0.0)                 | 8 (1.2)                   |
| Sub-Saharan Africa       | 37 (5.4)                | 0 (0.0)                 | 37 (5.5)                  |
| WHO income regions, n (%)|                         |                         |                           |
| High income              | 557 (80.6)              | 14 (82.4)               | 543 (80.6)                |
| Low income               | 30 (4.3)                | 0 (0.0)                 | 30 (4.5)                  |
| Lower-middle income      | 68 (9.8)                | 1 (5.9)                 | 67 (9.9)                  |
| Upper-middle income      | 36 (5.2)                | 2 (11.8)                | 34 (5.0)                  |
| Citizenship, n (%)       |                         |                         |                           |
| Italian                  | 553 (80.0)              | 14 (82.4)               | 543 (80.6)                |
| Not Italian              | 138 (20.0)              | 3 (17.6)                | 135 (20.0)                |
| Risk factors, n (%)      |                         |                         |                           |
| Blood transfusion        | 70 (10.1)               | 1 (5.9)                 | 69 (10.2)                 |
| Piercings or tatoos      | 61 (8.8)                | 1 (5.9)                 | 60 (8.9)                  |
| Risky sexual behaviour   | 33 (4.8)                | 0 (0.0)                 | 33 (4.9)                  |
| Intravenous drug users   | 3 (0.4)                 | 2 (11.8)                | 1 (0.1)                   |
| No one                   | 540 (78.1)              | 14 (82.4)               | 526 (78.0)                |
| Ever tested for HIV in life, n (%) |             |                         |                           |
| Yes                      | 219 (31.7)              | 7 (41.2)                | 212 (31.5)                |
| Not                      | 472 (68.3)              | 10 (58.8)               | 462 (68.5)                |
| HIV test, n (%)          |                         |                         |                           |
| Positive                 | 7 (3.2)                 | 0 (0.0)                 | 7 (3.3)                   |
| Negative                 | 186 (84.9)              | 5 (71.4)                | 181 (85.4)                |
| Unknown                  | 26 (11.9)               | 2 (28.6)                | 24 (11.3)                 |

---

Key points

In our study, we assessed the antibody positivity for hepatitis C using point-of-care-testing in subjects undergoing COVID-19 screening in the San Siro social-housing neighbourhood of Milan which is characterized by a multi-ethnical population and low socio-economic status. Seventeen (2.5%) of 691 subjects tested positive for HCV antibodies of whom 5 (29.4%) subjects were unaware of their serological status.
confirmed to be HCV-RNA positive and underwent direct-acting antivirals treatment at Luigi Sacco Hospital. One patient opposed any kind of follow-up, complaining about the location of the hospital chosen for ambulatory treatment, and consequently was extensively counselled to contact his general practitioner to proceed with the appropriate follow-up and treatment. Amongst the four patients aware of HCV-Ab positivity, who tested positive for HCV-Ab and denied having been treated in the past, three contradicted the previously administered questionnaire reporting to have been actually treated before, whereas one patient never answered the call.

Amongst the nine patients who tested negative for HCV-Ab but reported to be HCV Ab positive without a previous HCV treatment, two refused any kind of follow-up, two were confirmed to be HCV-Ab positive but HCV-RNA negative and five subjects later reported previous treatment which wasn’t initially reported in the questionnaire during the screening.

In our study, a prevalence of HCV Ab positivity of 2.5% was found, which is slightly lower than the estimates made on the general population of Northern Italy about 20 years ago (3.3%),\(^8\) with a proportion of subjects unaware of their serological status (29.4%), lower than the estimated 66% reported by a European study in 2015.\(^9\) Nevertheless, only one subject was confirmed to be HCV RNA positive (0.14%), again a lower figure than the 0.48% which was recently estimated in the Lombardy region.\(^10\)

In their study, D’Ambrosio et al.\(^2\) reported a prevalence of 0.10% for HCV Ab and 0.05% for HCV-RNA, a lower proportion than the one we found. This could be expected and it is mainly explained by the demographic composition of the population selected for the screening: our study population was older (median 64 years) when compared to that of D’Ambrosio et al. (range 32–52 years).\(^2\) In fact, we selected subjects >39 years older, as age is itself a risk factor for HCV infection, considering our limited RICTs supply.

Although the acceptance rate of HCV-Ab screening was satisfactory, our study underlines the extreme difficulty in linking to care of the subjects who tested positive (three of them refused a further clinical assessment and one subject never answered the phone call). A possible explanation for the difficulties in the follow-up could be represented by the absence of simultaneous HCV-RNA testing, not allowing to confirm an active infection and forcing the subject to attend a new medical appointment for venipuncture; this was worsened by the distance between the neighbourhood chosen for the study and Luigi Sacco Hospital, which rendered logistically difficult for patients—especially the ones with a low socio-economic status—to be followed up.

Moreover, it is possible that linguistic and cultural barriers could have rendered it difficult to explain the importance of HCV follow-up and treatment, even in the absence of any symptoms.

Our study opens several considerations related to the serological screening itself, which seems not to be effective enough in a population which is generally poorly linked to healthcare and potentially at high risk of carrying HCV infection. In particular, it could be useful to work on the creation of a path from POCT to treatment, ideally creating an efficient coordination between the general practitioner and the infectious diseases’ specialist in charge of treatment, and easy-to-access “checkpoints” for screening and treatment.\(^11,12\)

In conclusion, although the COVID-19 pandemic had negatively impacted the diagnosis, monitoring and treatment of liver disease

### Table 1 (Continued)

|                      | Overall, \(n = 691\) (100%) | Positive, \(n = 17\) (2.5%) | Negative, \(n = 674\) (97.5%) |
|----------------------|-----------------------------|-----------------------------|-----------------------------|
| **IgG SARS-CoV-2 results, \(n\)%** |                             |                             |                             |
| Positive             | 77 (11.1)                   | 2 (11.8)                    | 75 (11.1)                   |
| Negative             | 610 (88.3)                  | 15 (88.2)                   | 595 (88.3)                  |
| Doubt                | 4 (0.6)                     | 0 (0.0)                     | 4 (0.6)                     |
| **Aware of HCV status, \(n\)%** |                             |                             |                             |
| Yes                  | 31 (4.5)                    | 12 (70.6)                   | 19 (2.8)                    |
| Not                  | 660 (95.5)                  | 5 (29.4)                    | 655 (97.2)                  |
| **Previous treatment for HCV, \(n\)%** | Of 31                       | Of 12                       | Of 19                       |
| Yes                  | 19 (61.3)                   | 8 (66.7)                    | 10 (52.6)                   |
| Not                  | 7 (22.6)                    | 3 (25.0)                    | 5 (26.3)                    |
| Unknown              | 5 (16.1)                    | 1 (8.3)                     | 4 (21.1)                    |
| **Treatment for HCV, \(n\)%** | Of 19                       | Of 8                        | Of 10                       |
| More than 5 years ago| 12 (63.2)                   | 3 (37.5)                    | 9 (90.0)                    |
| Between 1 and 5 years ago | 5 (26.3)                   | 5 (62.5)                    | 0 (0.0)                     |
| Less than 1 year ago | 1 (5.3)                     | 0 (0.0)                     | 1 (10.0)                    |
| Unknown              | 1 (5.3)                     | 0 (0.0)                     | 0 (0.0)                     |

Abbreviations: IQR, inter quartile range; RICT, rapid immunochromatographic test.
in non-COVID-19 patients, we again underline the need to turn the challenge of the pandemic into an opportunity to screen, engage and link to care for people living with HCV. The effort should be particularly focused on those who face barriers related to socioeconomic situation, cultural and linguistic barriers or stigma, to achieve the WHO’s 2030 HCV elimination target.

**KEYWORDS**
awareness, COVID-19, diagnosis, elimination strategy, hepatitis C, rapid test

**ACKNOWLEDGEMENT**
The authors want to thank all the patients and personnel involved on a voluntary basis in the study.

**CONFLICT OF INTEREST**
AG has received consultancy fees from Mylan and non-financial educational support from Gilead. MG has received grants and fees for speaker bureaux, advisory boards and CME activities from BMS, Viiv, MSD, AbbVie, Gilead, Janssen and Roche. RR and AP are employees of Medispa SRL. All other authors have nothing to declare.

**DATA AVAILABILITY STATEMENT**
The data that support the findings of this study are available from the corresponding author upon reasonable request.

---

**FIGURE 1** Graphical representation of subjects reporting a previous HCV infection in the questionnaire according to be tested positive or negative at HCV Ab RICTs. RICTs, rapid immunochromatographic test.
RESEARCH LETTER

Malattie Infettive III Divisione, ASST FBF-Sacco, Milan, Italy
Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università degli Studi di Milano, Milan, Italy
Malattie Infettive, Ospedale Nuovo di Legnano, ASST Ovest Milanese, Legnano, Italy
Direzione Socio-Sanitaria, ASST FBF-Sacco, Milan, Italy

Correspondence
Andrea Giacomelli, III Infectious Diseases Unit, L. Sacco Hospital, Via G.B. Grassi 74, 20157 Milan, Italy. Email: andrea.giacomelli@asst-fbf-sacco.it; dott.giacomelli@gmail.com

ORCID
Martina Beltrami https://orcid.org/0000-0002-0095-9364
Gabriele Pagani https://orcid.org/0000-0002-1668-7543
Federico Conti https://orcid.org/0000-0002-8057-7488
Laura Pezzati https://orcid.org/0000-0002-7306-342X
Giacomo Casalini https://orcid.org/0000-0003-3685-4289

REFERENCES
1. Kondili LA, Craxì L, Andreoni M, Mennini FS, Razavi H. opportunistic co-screening for HCV and COVID-19-related services: a creative response with a need for thoughtful reflection. Liver Int. 2022;42(5):960-962. doi:10.1111/liv.15243
2. D'Ambrosio R, Rizzardini G, Puoti M, et al. Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination. Liver Int. 2022;42:1012-1016. doi:10.1111/liv.15216
3. Torre P, Annunziata M, Sciorio R, Coppola C, Masarone M, Persico M. Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno. Liver Int. 2022. doi:10.1111/liv.15273
4. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74:31-36.
5. Kondili LA, Andreoni M,Alberti A, et al. Estimated prevalence of undiagnosed HCV infected individuals in Italy: a mathematical model by route of transmission and fibrosis progression. Epidemics. 2021;34:100442.
6. Giacomelli A, Pagani G, Conti F, Bassoli C, Galli M. Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in northern Italy. J Hepatol. 2021;75(2):484-486. doi:10.1016/j.jhep.2020.12.026
7. Pagani G, Conti F, Giacomelli A, et al. Differences in the prevalence of SARS-CoV-2 infection and access to care between Italians and non-Italians in a social-housing Neighbourhood of Milan, Italy. Int J Environ Res Public Health. 2021;18(20):10621. doi:10.3390/ijerph182010621
8. Campello C, Poli A, Dal MG, Besozzi-Valenti F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection. 2002;30:7-12.
9. European Union HCV. Collaborators hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:325-336.
10. Kondili L. L’infezione cronica da virus dell’ epatite C (HCV) in Lombardia. Infez Med. 2021;S2:7-10.
11. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. WHO Advocacy brief. World Health Organization; 2016. Accessed April 8, 2022. https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/
12. Kondili L, Aghemo A, Andreoni M, et al. Milestones to reach hepatitis C virus (HCV) elimination in Italy: from free-of-charge screening to regional roadmaps for an HCV-free nation. Dig Liver Dis. 2022;54(2):237-242. doi:10.1016/j.dld.2021.03.026

How to cite this article: Beltrami M, Pagani G, Conti F, et al. HCV point of care screening in people tested for SARS-CoV-2 in a social-housing neighbourhood of Milan, Italy. Liver Int. 2023;43:251-255. doi:10.1111/liv.15375